Multi-drug delivery focuses on different signaling pathways in cancer cells that have synergistic anti-proliferative effects. In this study, we developed multi-prodrug nanocarriers (MPDNCs) consisting of poly (l-lysine)-carboxylate PTX (PLL-PTX) and hyaluronic acid-conjugated GEM (HA-GEM) for CD44-targeted synergistic biliary cancer therapy. An invitro study of cell viability and mRNA expression levels and an invivo study showed that MPDNCs more effectively inhibit proliferation in CD44-overexpressing cancer cells (HuCCT1) than in cells with lower CD44 expression (SCK) by synergistically inducing apoptosis. Consequently, these results demonstrate that MPDNCs are prodrugs with synergistic cancer therapeutic efficacy and effective cellular uptake at target cells compared to free drugs, indicating their strong potential as efficient multi-drug-carrying nano-platforms for cancer treatment.
|Number of pages||12|
|Publication status||Published - 2015 Jun 1|
Bibliographical noteFunding Information:
This work was supported by the Industrial Strategic Technology Development Program ( 10044021 , Development of nonvascular drug eluting stent for treatment of gastrointestinal disease) funded by the Ministry of Knowledge Economy (MKE, Korea). This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MEST) ( 2010-0019923 ).
© 2015 Elsevier Ltd.
All Science Journal Classification (ASJC) codes
- Ceramics and Composites
- Mechanics of Materials